The explosive popularity and soaring costs of GLP-1 diabetes and weight-loss drugs. The federal crackdown on pharmacy benefit managers. How the IRA interacts and conflicts with 340B. And of course, the fate of the battle over 340B rebates.
All figure to be big storylines in 2025, writes Tara Hanuscak, PharmD, MS, Chief Transformation Officer of The Craneware Group, in a recent essay published in MedCity News.
With a GOP trifecta now in control of the House, Senate and White House, there are a number of big pharmacy-related issues left over from last year, including whether Medicare and Medicaid will cover GLP-1 drugs for obesity, the fate of cheaper compounded versions of these drugs, and how Medicare Part D drug-price negotiation will work for 340B covered entities.
“Attorneys for both big pharma and the federal government will be busy in 2025,” writes Hanuscak. “Regulators will have their work cut out for them under a new administration that has expressed an anti-regulatory preference.”